MammoSite Radiation Therapy System (RTS) as the Sole Radiation Therapy Technique for Ductal Carcinoma In-Situ (DCIS)
45 Years
N/A
Female
DCIS
Trial Information
MammoSite Radiation Therapy System (RTS) as the Sole Radiation Therapy Technique for Ductal Carcinoma In-Situ (DCIS)
Data relevant to the evaluation of the efficacy and safety of the MammoSite RTS system in
providing radiation therapy to patients with DCIS will be collected. The MammoSite is a
radionuclide applicator designed to deliver internal radiation therapy (brachytherapy) in
patients with breast tumors following breast tumor resection surgery (lumpectomy).
Inclusion Criteria:
- Pre-Surgery:
- Unicentric pure DCIS
- Lesions should have a greatest dimension of 3 cm or less as determined by
pre-surgery mammography and MRI
- Post-Surgery:
- Negative histological margins confirmed prior to beginning radiation therapy.
- Margins are positive if there is tumor at the inked margin.
- Classified as low (NG1), intermediate (NG2) or high (NG3) nuclear grade DCIS,
using the Philadelphia Consensus Conference Guidelines are eligible
- Clinically node negative
Exclusion Criteria:
- Distance from the balloon surface to the surface of the skin < 5mm as determined by
CT imaging.
- Distant metastases.
- Invasive or in-situ lobular carcinoma (post-surgery assessment).
- Nonepithelial breast malignancies such as sarcoma or lymphoma.
- DCIS that is multicentric in the ipsilateral breast.
- Pregnant or lactating.
- Prior non-hormonal therapy for the present breast cancer, including radiation therapy
and/or chemotherapy.
- Collagen vascular diseases
- Coexisting medical conditions with life expectancy < 2 years.
- Serious psychiatric or addictive disorder
- Previously treated contralateral breast carcinoma
- Synchronous bilateral breast carcinoma.
- Other malignancy, except non-melanoma skin cancer, < 5 years prior to participation
in the study; the disease free interval from any prior carcinoma must be continuous.
- Patients with diffuse disease
Type of Study:
Interventional
Study Design:
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
Local Control Rate for Follow-up Period of 5 Years.
Outcome Description:
Failure of local control was defined as a histologically confirmed recurrence (invasive or non-invasive) within the prescription isodose volume. All recurrences were to have histological evaluation per the protocol; however, the case report forms did not provide space for this data to be captured. Ipsilateral axillary, infraclavicular, internal mammary, or supraclavicular recurrence or distant metastases were not considered treatment failures unless accompanied by ipsilateral breast failure.
Outcome Time Frame:
Data collected at the time of implant, radiation therapy, and at the patient's 3 month, 6 month, 1 year, 2 year, 3 year, 4 year and 5 year follow-up visits.
Safety Issue:
Yes
Principal Investigator
Oscar Streeter, MD
Investigator Role:
Principal Investigator
Investigator Affiliation:
University of Southern California
Authority:
United States: Food and Drug Administration
Study ID:
MS-700
NCT ID:
NCT00586326
Start Date:
August 2003
Completion Date:
April 2011
Related Keywords:
- DCIS
- MammoSite
- DCIS
- Carcinoma
- Carcinoma in Situ
- Carcinoma, Intraductal, Noninfiltrating
- Carcinoma, Ductal, Breast
- Carcinoma, Ductal
Name | Location |
|---|---|
| Fox Chase Cancer Center | Philadelphia, Pennsylvania 19111 |
| Rhode Island Hospital | Providence, Rhode Island 02903 |
| Swedish Cancer Institute | Seattle, Washington 98104 |
| William Beaumont Hospital | Royal Oak, Michigan 48073 |
| Cedars Medical Center | Miami, Florida 33136 |
| Virginia Commonwealth University | Richmond, Virginia |
| University of Southern California | Los Angeles, California 90033 |
| St. Agnes Hospital | Baltimore, Maryland 21229 |
| Arizona Oncology Services | Phoenix, Arizona 85032 |
| Daniel Freeman Hospital | Inglewood, California 90301 |
| NY Presbyterian | New York, New York 10065 |
| MD Anderson Cancer Clinic | Houston, Texas 77030 |
